Thiazolidinediones and cardiovascular disease

Medical Letter on Drugs and Therapeutics

Volumn 49, Issue 1265, 2007, Pages 57-58

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG EFFECT; EDEMA; FOLLOW UP; GLYCEMIC CONTROL; HAZARD RATIO; HEART INFARCTION; HUMAN; INCIDENCE; MONOTHERAPY; MORTALITY; PREVENTION AND CONTROL; SHORT SURVEY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; WEIGHT GAIN; ANIMAL; ARTICLE;

ANIMALS; HEART FAILURE, CONGESTIVE; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL INFARCTION; THIAZOLIDINEDIONES;

EID: 34547584189     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (11)

1. Drugs for diabetes. Treat Guidel Med Lett 2005; 3:57.
2. SE Nissen and K Wolski. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457.
3. RW Nesto et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108:2941.
4. S Yaturu et al. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 2007; 30:1574.
5. SM Haffner et al. Effects of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106:679.
6. T Mazzone et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296:2572.
7. RB Goldberg et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28:1547.
8. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006; 368:1096.
9. SE Kahn et al. Glycemic durability of rosiglitazone, metformin or glyburide monotherapy. N Engl J Med 2006; 355:2427.
10. PD Home et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007; 357:28.
11. JA Dormandy et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005; 366:1279.